Glaukos Way Ahead Of The Glaucoma Competition
September 23, 2016 at 13:53 PM EDT
Cantor Fitzgerald reiterated its Buy rating and $41 price target on Glaukos Corp (NYSE: GKOS) after the company reported efficacy data ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.